Disco Pharmaceuticals closed a €36 million seed round (final close) to advance its surfaceome discovery platform toward preclinical development. The funding will support target validation and early lead optimization for novel cell‑surface targets, with the company citing plans to nominate development candidates and expand its discovery engine. Investors in the round include venture backers focused on platform‑driven target discovery; Disco said the capital positions the company to accelerate translational programs and attract pharma partnerships. The raise underscores continued investor appetite for surfaceome and target‑discovery technologies despite broader market volatility. The financing also signals that early‑stage platform startups can secure meaningful seed checks to push toward IND‑enabling activities.